Mantle cell lymphoma (MCL) is subtype of B cell nonHodgkin lymphoma (NHL) with a hetergenous and generally aggressive disease course. In the frontline setting, intensive chemo-immunotherapy remains the standard of care for patients 65 years of age or younger, achieving a high number of durable complete responses (Chihara et al, 2016) ; however, patients invariably relapse and develop long term toxicities. Single agent studies with drugs such as lenalidomide, bortezomib and temsirolimus, have reported modest efficacy in patients with relapsed or refractory MCL (RR-MCL) (Goy et al, 2009 (Goy et al, , 2013 Zinzani et al, 2013; Trneny et al, 2016) , and the efficacy has improved after the addition of rituximab. (Ansell et al, 2011; Wang et al, 2012) Clinical trials with newer agents, such as ibrutinib (Wang et al, 2015; Rule et al, 2017) , acalabrutinib (Wang et al, 2018) and venetoclax (Davids et al, 2017) have reported significant efficacy and safety profile in patients with RR-MCL.
Ibrutinib and acalabrutinib are orally administered inhibitors of Bruton tyrosine kinase (BTK). The advent of ibrutinib has seen a paradigm shift in the treatment of patients with small lymphocytic lymphoma/chronic lymphocytic leukaemia (SLL/CLL) and MCL. Based on the remarkable results from single agent ibrutinib (Wang et al, 2013) as well as ibutinib combined with rituximab (IR) , BTK inhibitors are approved in MCL and are under active investigation in clinical trials, in combination with venetoclax and/or chemo-immunotherapy regimens in patients with MCL (NCT02558816, NCT03112174, NCT03295240, NCT02717624).
We previously reported that IR is a very active and safe regimen in RR-MCL , generating an objective response rate (ORR) of 88% with 44% complete remission (CR) . In this update, we describe the long-term efficacy and safety profile of the IR combination in MCL.
Patients and methods

Study overview
This study was an open-label, single arm and single-centre prospective phase 2 trial in patients with RR-MCL. Details of the inclusion, exclusion criteria, treatment schedule, study design, follow-up and response assessment were reported previously . Patients were enrolled between 15 July 2013 and 30 June 2014 and were followed up until January 2018. This study was developed by the investigators with support from Pharmacyclics, Inc. and was approved by The University of Texas MD Anderson Cancer Center institutional review board. Informed consent was obtained in accordance with institutional guidelines and the Declaration of Helsinki. Patient charts were reviewed to update the long term follow-up. Treatment compliance was checked at every patient visit by reviewing patient diaries for ibrutinib intake. Adverse effects were categorized according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (CTCAE) version 4.0 [http://evs.nci.nih. gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_ 5x7.pdf (accessed April 22, 2015) .]. Information regarding minimal residual disease (MRD) was unavailable. Intent to treat analyses were performed. Event-free survival (EFS) was calculated from the start of IR to the date of discontinuing ibrutinib, i.e. event (toxicity, consolidation stem cell transplantation (SCT), progression, death or other, whichever occurred first). Duration of response (DOR) was reported from the date of achieving response to the last follow-up date on which the response was recorded as lost or sustained. For DOR, patients who discontinued treatment for causes other than progression were censored at the time of discontinuation. Progression-free survival (PFS) was calculated from treatment start to the date of progression/death, whichever occurred first (patients who progressed after discontinuing ibrutinib due to causes other than progression and went on to receive subsequent treatments were censored at the time of discontinuation). Overall survival (OS) was calculated from treatment start to the date of last follow-up/death. Survival endpoints were analysed using the Kaplan-Meier method and differences calculated by the log-rank test. P < 0Á05 were considered statistically significant. Statistical analyses were conducted using GraphPad Prism version 6.00 for Windows (GraphPad Software, La Jolla, CA).
Results
Patients and treatment
A total of 50 patients (median age 68 years, range 45-85 years) with RR-MCL were included in the study (baseline patient characteristics were described previously) . Sixteen patients (32%) were over the age of 70 years. The majority were males (76%), had an Eastern Cooperative Oncology Group) performance status of 0-1 (100%), and were previously treated for MCL (median of 3 prior therapies, range 1-6). Blastoid morphology was observed in 14% and the distribution of patients according to the MCL International Prognostic Index (MIPI) risk score was low risk (14%), intermediate risk (50%) and high risk (36%) (Hoster et al, 2014) . The proportion of patients with Ki67% ≥50% (high Ki67%) was 22% and 77% had low Ki67% (i.e. <50%) while the proportion of patients with Ki67% ≥30% was 53%.
Overall, the median follow-up time was 47 months (range 1-52 months). The median duration on treatment was 16 months (range 1-51 months). With extended follow-up, the ORR was 88% [CR in 58% (n = 29) and partial remission (PR) in 30% (n = 15). Compared to the original report , seven patients improved from PR to CR over time, increasing the CR rate. Three patients (6%) had stable disease and another 3 had primary progressive disease. Overall, 38 patients had discontinued treatment (76%) and 12 (24%) remained on study. All 12 of the patients who remained on study had maintained CR at the time of last follow-up. Among the 38 patients who discontinued treatment, 14 patients (28%) discontinued treatment primarily due to disease progression (including two patients due to blastoid transformation), 9 due to intolerance (18%), 7 for consolidation SCT (14%; response status at SCT was CR, n = 5, PR, n = 2), 4 due to diagnosis of a second cancer while on therapy (after a median of 11 months after starting treatment), 3 for other miscellaneous causes (travel issues, patient choice and financial issues) and one patient died of unclear aetiology while in remission and receiving therapy.
The clinical characteristics of patients who progressed (n = 23) are detailed in Table I (this includes patients who progressed while on IR and 9 additional patients who discontinued therapy due to causes other than disease progression but progressed/died thereafter). Three patients who were non-responders had high risk MIPI score and 2 of these 3 patients had blastoid morphology.
Long term outcomes
After a median follow-up of 47 months, the median EFS was 16 months ( Fig 1A) and a total of 37 events lead to treatment discontinuation. The median number of treatment cycles was 17 (range 1-56) and 20 patients (40%) received ≥24 cycles. The median DOR was 46 months (range 1-48 months; Fig 1B) . Twenty-one (68%) patients had a DOR ≥ 24 months. Among the 10 patients who had <24 months DOR, 90% had intermediate or high risk MIPI score. Overall, 23 patients progressed/died (46%). The median PFS was 43 months (range 1-48 months; 3-year PFS 54%, Fig 1C) . In the sub-group analysis, patients with nonblastoid morphology and low/intermediate risk MIPI showed a trend of better PFS compared to blastoid and high risk MIPI categories (Fig 2A, had significantly longer PFS (median not reached) compared with the high Ki67% category (median 8 months) (P < 0Á0001, Fig 2C; 3-year PFS was 68% vs. 1% in low and high Ki67% respectively). Overall, 18 patients (36%) died. Fourteen deaths were due to progressive disease (78%) and four patients died due to other causes (3 due to second cancers and one patient died with multiorgan failure from unknown aetiology and sudden death while still in remission and receiving therapy). The median OS has not been reached, 3-year survival 69% (Fig 1D) . In sub-group analysis, patients with non-blastoid morphology showed a trend for longer survival compared to blastoid morphology (Fig 2D ; P = 0Á15) while patients with low and intermediate risk MIPI demonstrated a significantly longer OS compared to high risk MIPI (P = 0Á04, Fig 2E; 3-year survival was 44% in high risk vs. 98% and 75% in low/ intermediate risk MIPI respectively). Similarly, those with low Ki67% had significantly longer survival compared to high Ki67% (P < 0Á0001, Fig 2F; 3-year survival was 27% in high Ki67% and 81% in low Ki67% group respectively).
Seven patients (14%) came off study for SCT. Among these 7 patients, 2 progressed after SCT (one died with progressive disease and another restarted on IR off study). Six patients were alive and in remission. None of these 7 patients had high risk MIPI score.
The median number of subsequent therapies among the 14 patients who discontinued IR study primarily for disease progression was 2 (range 0-9). Among these 14, 10 patients died and 4 were alive at the time of last follow-up.
Long term safety
The median number of IR treatment cycles was 17 (range 1-56). Eighteen patients (36%) required dose reduction in ibrutinib: 3 patients reduced from 560 to 420 mg, 8 patients reduced from 560 to 280 mg and 6 patients from 560 to 140 mg at the time of last follow-up. Most common causes of dose reduction were toxicities, including infections, skin rashes, neutropenia, oral ulcers, fatigue and atrial fibrillation (alone or in combination). The toxicities that were probably related to IR treatment are shown in Table II . The pattern of distribution of toxicities was similar to the original report . The most common haematological and non-haematological grade 1-2 adverse events included fatigue, diarrhoea, myalgia nausea, atrial fibrillation, vomiting, mucositis, dyspnea, dizziness, peripheral neuropathy, ocular symptoms, lower extremity oedema, cough and fever. Overall, none of the deaths were related to IR combination. A few additional grade 3 adverse events were reported with the longer follow-up, but none had grade 4 toxicity. One patient grade 3 anaemia and three additional grade 3 infectious complications were noted (pneumonia, sinusitis and enterocolitis), as well as one instance each of grade 3 diarrhoea, pleural effusion and hypeuricaemia. There were no additional episodes of grade 3-4 bleeding or atrial fibrillation. After the extended follow-up, none demonstrated ibrutinib-induced lymphocytosis, which was probably subdued due to the co-administration of rituximab and resolved early in the therapy.
Discussion
Single agent ibrutinib has shown significant efficacy in patients with RR-MCL (Wang et al, 2013 (Wang et al, , 2015 . In this 4 years follow-up report from a phase II combination trial of ibrutinib with rituximab (IR), we demonstrated that the IR combination is efficacious without long term toxicities, can induce durable remissions and improve survival in a fraction of patients with RR-MCL. To the best of our knowledge, these results are the longest follow-up data from any ibrutinib-based study in patients with RR-MCL. Our results further consolidate the efficacy and safety results seen with ibrutinib in previous studies from heavily pre-treated patients with RR-MCL (Wang et al, 2015) . Notably, after a 4-year follow-up, the ORR did not change significantly; however, the CR rate improved to 58% and the median DOR was 46 months. The median PFS was 43 months and the median OS was not reached. Although 77% patients were off study at the time of last follow-up, only 28% discontinued IR due to overt disease progression and rest discontinued therapy for other reasons. Particular benefit was noted in patients with low Ki67% (<50%), because they achieved significantly longer PFS and OS as compared to those with high Ki67%. As expected, patients with non-blastoid morphology and low risk MIPI score demonstrated a trend for longer PFS and OS. These outcomes are significant in the RR-MCL setting where most of the non-transplant treatment modalities do not induce durable responses.
Our results appear to be favourable compared to single agent ibrutinib (Wang et al, 2015; Rule et al, 2017) (albeit with 26Á7 months follow-up). The CR rate with IR was 58% compared to 23% for single agent ibrutinib and the median PFS and OS were 43 months and not reached in this IR study, vs. 13 and 22Á5 months in single agent ibrutinib. Although the median follow-up times were different in the three reports, we believe that the addition of rituximab has improved the outcome as compared to single agent ibrutinib studies and has done so without significant additional toxicity. These differences could also be explained by the fact that the proportion of patients with high risk MIPI were slightly lower in the IR combination 36% vs. 49% in patients studied with single agent ibrutinib. The improvement in CR with IR appears to be similar to what was observed after longer follow-up with ibrutinib in SLL/CLL (Coutre et al, 2017) . However, in the absence of randomized controlled trials and large sample size, we cannot make a statement whether the addition of rituximab to ibrutinib improved survival compared to data from single agent ibrutinib studies.
Single agent ibrutinib alone has been shown to be superior to temsirolimus in a randomized phase 3 clinical trial (n = 280) . Furthermore, results with the IR combination are favourable in RR-MCL (88% ORR and 58% CR) when compared to other agents, such as lenalidomide [ORR of 28% and 7Á5% CR in the EMERGE trial (Goy et al, 2013) and in a phase II study with rituximab (Wang et al, 2012) , ORR was 57% and 36% CR], temsirolimus alone [ORR of 22-47% in two studies respectively (Hess et al, 2009; Rule et al, 2018) ] or in combination with rituximab (Atilla et al, 2017) and in idelalisib (ORR of 40% and CR of 5%) (Kahl et al, 2014) . With these encouraging results with IR, we have initiated a frontline trial in MCL, with IR as induction therapy followed by consolidation with hyper-CVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone plus methotrexate and cytarabine)-based regimens -(NCT02427620).
Of note, the major limitations of this study include the small sample size, lack of next generation/whole exome sequencing-based mutation analysis in sequential samples, lack of karyotype data and sequential collection of MRD data using highly sensitive sequencing.
Of note, 28% patients progressed while on treatment with IR and discontinued therapy; most of these patients' baseline characteristics included blastoid morphology, high Ki67% and high MIPI score. These results are similar to those reported with a pooled analysis in the single agent ibrutinib (Rule et al, 2017) . Furthermore, the survival of patients with blastoid morphology was inferior. These results are thought-provoking in the context of our growing understanding of the pathobiology of ibrutinib-refractory MCL. It has been shown that patients with blastoid morphology have a constitutive phosphorylation of AKT (Rudelius et al, 2006) . Of note, unlike CLL (Woyach, 2015) , the BTK or PLCG1 gene mutations were uncommon in patients with MCL who relapsed on ibrutinib therapy (Martin et al, 2016) . It is also unclear whether patients with high Ki67% require additional chemotherapy to induce long lasting response as compared to those with low Ki67%. These findings prompt the development of newer strategies to understand the pathobiology of blastoid MCL and ibrutinib-refractory MCL and identify predictive biomarkers for ibrutinib resistance in patients with RR-MCL.
Similar to the long-term data from single agent ibrutinib, the extended safety profile for IR did not show any additional long term toxicities (Wang et al, 2015) . The commonest grade 1-2 toxicities were fatigue, diarrhoea, myalgia and nausea, which was previously reported (Wang et al, 2015) . There were no emergent unexpected serious toxicities. In particular, we did not notice any additional grade 3-4 serious adverse events related to ibrutinib, such as atrial fibrillation, bleeding or unexpected deaths. Three additional grade 3-4 infectious episodes were reported. Overall, the regimen was well tolerated with a manageable safety profile; however 9 patients discontinued due to intolerance to ibrutinib and switched to other therapies. Consistent with our previous report , ibrutinib-associated redistribution lymphocytosis was not observed at extended follow-up.
To conclude, IR combination is safe and efficacious in patients with RR-MCL, significantly prolonged survival in a subset of patients with RR-MCL and has a favourable impact on long-term outcome in RR-MCL when compared to data from other non-transplant modalities. Unfortunately, this is not a curative regimen, and specific subsets of MCL, such as blastoid morphology, high risk MIPI and high Ki67% (≥50%), continue to pose a therapeutic challenge. Further studies are needed to understand the pathobiology of these subsets of MCL.
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